Polygenic architecture informs potential vulnerability to drug-induced liver injury by Koido, Masaru et al.
1 
 
Polygenic architecture informs potential vulnerability to 1 
drug-induced liver injury  2 
 3 
Authors and affiliations: 4 
Masaru Koido1,2,#, Eri Kawakami2,3,#, Junko Fukumura1,2, Yui Noguchi1,2, Momoko 5 
Ohori2,3, Yasunori Nio2,3, Paola Nicoletti4, Guruprasad P. Aithal5, Ann K. Daly6, Paul B. 6 
Watkins7, Hisashi Anayama8, Yvonne Dragan9, Tadahiro Shinozawa2,3,8 and Takanori 7 
Takebe1,2,3,10,11,12,13* 8 
1. Department of Regenerative Medicine, Yokohama City University Graduate School of 9 
Medicine, Kanazawa-ku 3-9, Yokohama, Kanagawa 236-0004, Japan. 10 
2. Organoid medicine project, T-CiRA joint program, Fujisawa, Kanagawa 251-8555, 11 
Japan 12 
3. Regenerative Medicine Unit, Takeda Pharmaceutical Company Ltd, Fujisawa, 13 
Kanagawa 251-8555, Japan 14 
4. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount 15 
Sinai, New York, USA 16 
2 
 
5. NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals 17 
NHS Trust and the University of Nottingham, Nottingham, UK. 18 
6. Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle 19 
University, Newcastle upon Tyne, UK. 20 
7. Institute for Drug Safety Sciences, UNC Eshelman School of Pharmacy, University of 21 
North Carolina, Chapel Hill, North Carolina, USA 22 
8. Drug Safety Research and Evaluation, Takeda Pharmaceutical Company Ltd, 23 
Fujisawa, Kanagawa 251-8555, Japan 24 
9. Global Discovery and Investigative Toxicology, Takeda Pharmaceuticals, 35 25 
Landsdowne St, Cambridge, MA 02139, USA 26 
10. Institute of Research, Tokyo Medical and Dental University 1-5-45 Yushima, 27 
Bunkyo-ku, Tokyo 113-8510, Japan 28 
11. Division of Gastroenterology, Hepatology and Nutrition & Division of Developmental 29 
Biology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, 30 
OH 45229-3039, USA 31 
12. The Center for Stem Cell and Organoid Medicine (CuSTOM), Cincinnati Children’s 32 
Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229- 3039, USA. 33 
3 
 
13. Department of Pediatrics, University of Cincinnati College of Medicine, 3333 Burnet 34 
Avenue, Cincinnati, OH 45229-3039, USA 35 
# These authors contributed equally to this work. 36 






Drug-Induced-Liver-Injury (DILI) is a leading cause of termination in drug development 41 
programs and removal of drugs from the market, and this is partially due to the inability 42 
to identify patients who are at risk1. Here, we developed a polygenic risk score (PRS) for 43 
DILI by aggregating effects of numerous genome-wide loci identified from previous 44 
large-scale genome-wide association studies (GWAS)2. The PRS predicted the 45 
susceptibility to DILI in patients treated with fasiglifam, amoxicillin-clavulanate or 46 
flucloxacillin, and in primary hepatocytes and stem cell-derived organoids from multiple 47 
donors treated with over 10 different drugs. Pathway analysis highlighted processes 48 
previously implicated in DILI, including unfolded protein responses and oxidative stress. 49 
In silico screening identified compounds that elicit transcriptomic signatures present in 50 
hepatocytes from individuals with elevated PRS, supporting mechanistic links and 51 
suggesting a novel screen for safety of new drug candidates. This genetic-, cellular-, 52 
organoid- and human-scale evidence underscored the polygenic architecture underlying 53 
DILI vulnerability at the level of hepatocytes, thus facilitating future mechanistic studies. 54 
Moreover, the proposed “polygenicity-in-a-dish” strategy might potentially inform 55 





 Polygenic risk scores encompassing cumulative effects of tens of thousands to 59 
hundreds of thousand variants or genome-wide variants, can identify individuals at high 60 
risk of common diseases3. However, it remains unclear whether a polygenic model can 61 
account for susceptibility to relatively rare diseases such as drug-induced liver injury 62 
(DILI). 63 
 DILI is one of the leading causes of termination in drug development programs 64 
and drug withdrawals from the market; in clinical practice, it is also associated with 65 
substantial morbidity and mortality1. Genome-wide association studies (GWAS) 66 
conducted by the international Drug-Induced Liver Injury Consortium (iDILIC) and the 67 
Drug-Induced Liver Injury Network (DILIN) have identified several significant variants 68 
associated with DILI due to multiple different drugs (P-value from GWAS (PGWAS) < 69 
5×10−8)2. Since each variant has modest predictive impact, we herein revisited GWAS 70 
findings to determine whether the polygenic score, which sums up effects of numerous 71 
variants, informs potential DILI susceptibility in humans. The goal of this study was to 72 
develop a polygenic risk scores (PRS) using data from previous GWAS (performed by 73 
iDILIC and DILIN) and to validate their performance characteristics in GWAS data 74 
obtained from an independent clinical trial of a hepatotoxic drug, as well as multiple 75 
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donor-derived organoids and primary hepatocytes treated with a variety of hepatotoxic 76 
medications. We also used the derived PRS to identify mechanisms underlying the 77 
susceptibility to DILI. 78 
 To assess the polygenicity associated with susceptibility to DILI, summary 79 
statistics of a GWAS from the iDILIC/DILIN collaboration which studied cases of DILI 80 
due to selected drugs were used for the discovery dataset, including all patients 81 
(ALL-DILI GWAS, n=862), hepatocellular (HC-DILI GWAS, n=474) and 82 
cholestatic/mixed (CM-DILI GWAS, n=323) and compared with those of 83 
population-matched controls (n=10,588) (Figure 1a and Extended Data Fig.1; see 84 
details in ref#2). In the original report by iDILIC/DILIN, two loci in the entire cohort 85 
(ALL-DILI), one locus in CM-DILI GWAS and a locus in HC-DILI GWAS, were 86 
genome-wide significant (PGWAS < 5×10
−8)2. Herein, we hypothesized that polygenic 87 
architecture informed by iDILIC/DILIN GWAS would predict the susceptibility of an 88 
independent DILI GWAS dataset, namely patients who experienced liver injury during 89 
the clinical trials of TAK-875 (fasiglifam). As linkage disequilibrium (LD) score regression 90 
is inappropriate with the relatively small sample size in GWAS study4, we sought to 91 
investigate the polygenic architecture of DILI susceptibility by comparing two 92 
independent DILI GWAS. 93 
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 TAK-875 is an oral, highly potent, and selective FFAR1 (GPR40) agonist, the 94 
first of its class tested for glucose-lowering ability in type 2 diabetes patients5. TAK-875 95 
development was discontinued owing to the rare DILI incidence detected in a Phase 3 96 
study6. We recruited 43 TAK-875 DILI patients (cases) and 129 matched patients who 97 
did not experience liver injury when treated with TAK-875 in the clinical trials (controls) 98 
for subsequent GWAS. The TAK-875 cases and controls were not included in the 99 
iDILIC/DILIN GWAS. Although an increase in ALT levels was observed after treatment 100 
with TAK-875 in the DILI patients, total bilirubin was also increased (Extended Data 101 
Fig.2) consistent with experimental models that have demonstrated an inhibition of bile 102 
acid transporters by TAK-875 treatment7. After QC analysis and genome-wide genotype 103 
imputation using populations from 1000 Genomes Phase 3 (1KGP3) as a reference, 39 104 
TAK-875 DILI cases and 122 controls who were self-reported Caucasians with 105 
13,477,278 autosomal variants and 184,010 non-imputed variants were selected for 106 
further study (Extended Data Fig.1 and 2c-e; Supplementary Table S1). Logistic 107 
regression analysis with covariates for population structure yielded no genome-wide 108 
significant association signals in the GWAS (Figure 1b).  109 
 After iDILIC/DILIN GWAS summary statistics were clumped by linkage 110 
disequilibrium (LD) in the European population, we performed shared genetic aetiology 111 
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analysis to determine whether the iDILIC/DILIN GWAS signals correlated with TAK-875 112 
DILI GWAS signals using maximal inclusion of single nucleotide polymorphisms (SNPs) 113 
with PGWAS<0.5 (Figure 1c). Interestingly, comparing GWAS results showed that 114 
iDILIC/DILIN GWAS for CM-DILI (Figure 1c) shared genetic aetiology with TAK-875 DILI 115 
more than did the iDILIC/DILIN GWAS for ALL- or HC-DILI did (Extended Data Fig.2f,g), 116 
indicating that susceptibility to TAK-875 DILI is genetically linked to CM-DILI 117 
susceptibility to many other drugs. 118 
Functional enrichment analysis of summary statistics for iDILIC/DILIN CM-DILI 119 
was performed using GARFIELD (GWAS analysis of regulatory or functional information 120 
enrichment with LD correction) software using default annotations including >1000 121 
publicly available datasets with regulatory genomic regions 8. The strongest enrichment 122 
in the epigenetic state was observed in HepG2 cells vs cells of other origin (Figure 1d, 123 
left), suggesting that a substantial genetic susceptibility for CM-DILI resides within the 124 
hepatocyte-like cellular context. The strongest enrichment in a genic state was in the 5’ 125 
untranslated region (UTR) (Figure 1d, right). The Pascal (pathway scoring algorithm)9 126 
revealed that association signals of CM-DILI GWAS were enriched in experimentally 127 
proposed pathways for DILI, including mitochondrial activity, oxidant-induced survival10, 128 
and unfolded protein response (UPR)11 (p<0.05, Figure 1e and Supplementary Table 129 
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S2). Thus, genetic annotation of genome-wide CM-DILI GWAS signals reasonably 130 
reflect reported molecular and cellular pathways related to human DILI. We hereafter 131 
defined the CM-PRSgw (genome-wide PRS) by aggregating 27,740 SNPs in and near 132 
hepatocyte-expressed genes with PGWAS<0.5 for further analysis (see Methods). 133 
 Although CM-PRSgw is solely formed by a iDILIC/DILIN study that does not 134 
include TAK-875 subjects, the TAK-875 DILI case samples had a marginally higher 135 
CM-PRSgw score distribution than control samples (AUROC 0.61 (95% CI: 0.51-0.71), P 136 
for two-tailed Wilcoxon–Mann–Whitney U test<0.05) (Figure 1f and Extended Data 137 
Fig.3). Interestingly, there was a trend towards an increase in the baseline values of ALT, 138 
AST, and total bilirubin as the CM-DILI PRSgw increased in all TAK-875 treated patients 139 
(Extended Data Fig.4). We also found that CM-DILI PRSgw potentially predicted 140 
susceptibility to DILI of 167 flucloxacillin or 207 amoxicillin-clavulanate patients with a 141 
CM-DILI phenotype (AUROC 0.61 (95%CI: 0.57–0.66) or 0.62 (0.58–0.66), 142 
respectively; Extended Data Fig.5; see Supplementary Note and Supplementary 143 
Methods). These cases were not included in the original CM-DILI PRS determinations2 144 
but described elsewhere (see Cirulli et al12). These data support that the 145 
cholestatic/mixed polygenic score (CM-PRSgw) could predict the potential DILI 146 
susceptibility of patients caused by multiple different drugs. Notably, when CM-DILI 147 
10 
 
GWAS added 157 flucloxacillin and 320 amoxicillin-clavulanate DILI patients (Figure 1a), 148 
the GWAS signals were also enriched in plausible biological pathways and 149 
hepatocyte-like context (Extended Data Fig.6, and Supplementary Table S3), and its 150 
derived PRS, named CM-PRSgw+, was comparable to the above in terms of 151 
distinguishing TAK-875 DILI cases from controls (Figure 1f and Extended Data Fig.3; 152 
see Supplementary Note). 153 
Next, we investigated whether the two different PRSs could stratify DILI vulnerability 154 
under CM-DILI conditions using both a scored human hepatocyte model and human 155 
liver bud organoids (HLOs) derived from iPSC (Figure 2a). Primary human hepatocytes 156 
(PHH), the gold standard for toxicology testing (and a fully matured adult cell type) were 157 
randomly selected from vendors (Supplementary Table S4). Multi-donor iPSCs were 158 
obtained from the cell bank, Coriell Institute and the European Bank for Induced 159 
Pluripotent Stem Cells (EBiSC) (Supplementary Table S5). Whole-genome genotypes 160 
of purchased PHH and iPSCs from healthy European (EUR) donors were determined 161 
by SNP array to calculate their CM-PRSgw and CM-PRSgw+ (see Methods). PHH (21 162 
donors) and iPSC-HLOs (5 donors) in this study were selected after a battery of quality 163 
control experiments (Extended Data Fig.7 and 8). For the modelling the CM- DILI 164 
phenotypes with the iPSCs, we adopted modified protocols of previously reported 165 
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vascularized 3D iPSC-HLOs13. All the donor iPSC successfully generated HLOs with 166 
consistent expression of liver-associated proteins (Albumin and bile salt export pump; 167 
BSEP), and CYP3A4 activity (Extended Data Fig.7a-d). HLOs that were exposed to 168 
cholyl-lysyl-fluorescein (CLF), a fluorescently labelled bile acid, displayed prominent 169 
accumulation of bile acids under cyclosporin A (CsA) treatment, followed by massive 170 
cell death (Extended Data Fig.7e, f). Hereafter we used this as a model for assessing 171 
CM-DILI by iPSC-HLOs. For the modelling of the CM-DILI phenotypes from PHH cells, 172 
we analysed the viability based on established cholestatic-type DILI protocols14 by 173 
pre-treatment with lithocholic acid (LCA), a highly toxic secondary bile acid (Extended 174 
Data Fig. 9 a-f). 175 
Under the cholestatic conditions, we evaluated the toxicity of 12 DILI drugs, 176 
cyclosporine, bosentan, troglitazone, diclofenac, flutamide, ketoconazole, 177 
carbamazepine, amoxicillin-clavulanate and methapyrilene (drugs that produce DILI 178 
with a CM phenotype), tacrine, acetaminophen (APAP), tolcapone (drugs that produced 179 
DILI with an hepatocellular phenotype), to determine if the score-dependent trend is 180 
conserved across multiple drugs (Figure 2a). The correlation patterns were plotted 181 
between the two different PRS and cell viability for each drug treatment (Figure 2b). 182 
CM-PRSgw and the cell death rate under drug treatment were well correlated, and the 183 
12 
 
average Pearson correlation coefficient of each category of drugs used in the 184 
experiment was more significant than that of CM-PRSgw+(Figure 2c), Thus, by 185 
examining the correlation comparison using iPSC-HLOs and PHH cells, we found that 186 
CM-PRSgw is more strongly correlated with the toxicity evaluation of the DILI drugs than 187 
CM-PRSgw+ (Figure 2b and 2c). Intriguingly, the five-donor iPSC-HLO without LCA 188 
pre-treatment also revealed a correlation between cell viability under CsA treatment and 189 
the CM-PRSgw (P < 0.05), whereas CM-PRSgw+ showed no obvious correlation 190 
(Extended Data Fig. 9g,h). CM-PRSgw+ was developed from GWAS of our original 191 
cohort plus 477 patients with DILI due to either amoxicillin-clavulanate or flucloxacillin 192 
so that almost half of the cases used to derive CM-PRSgw+ were just due to these two 193 
drugs. The fall-off in prediction suggests that CM-PRSgw+ may not be able to identify 194 
DILI liability for all drugs in our experimental models. Taken together, these data show 195 
that the CM-DILI PRSgw-based stratification approach in the multi-donor PHH- and 196 
iPSC-HLO-based assay was more widely applicable than PRSgw+-based one. 197 
To approach functional pathways associated with CM-DILI risks, we first performed 198 
comparative transcriptome analysis of basal expression levels in the cells in culture, 199 
regressing out five transcriptome principal components to capture experimental 200 
variability15 (Figure 3a). Unbiased pathway enrichment analysis in 10 PHH donors 201 
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revealed that genes involved in mitochondria and translation were inactivated in the 202 
higher CM-PRSgw donors (FDR<0.01; Figure 3b and Supplementary Table S6). We next 203 
determined the CM-PRSgw in 157 donors of human liver samples that have undergone 204 
RNA profiling16. There too, the donors with the highest CM-PRSgw scores appeared to 205 
have the same pathways inactivated as we observed in the 10 PHH donors (Figures 3a, 206 
3b, and Supplementary Table S7; see Methods). In addition, basal expression levels of 207 
mitochondrial genes and UPR-related genes were correlated with the CM-DILI PRSgw in 208 
the transcriptome analysis of 5 donor iPSC-HLOs (Figures 3c). These data suggest that 209 
global transcriptional and translational processes might be perturbed in the people who 210 
are susceptible to CM-DILI, consistent with findings of GWAS-signal enrichments in 211 
5’UTR region (Figure1e). 212 
Based on these pathway extractions, we further investigated CM-DILI 213 
vulnerability mechanisms using an iPSC-HLO model focusing on mitochondrial activity 214 
and ER stress signals under CsA treatment. Consistently, we observed cholestatic cell 215 
death with elevated UPR-associated proteins, massive ROS production and functional 216 
mitochondria depletion in iPSC-HLO (Figure 3d-f and Extended Data Fig. 10). In 217 
agreement with this, an antioxidant GSH/GSSG ratio was elevated more under CM-DILI 218 
drug treatment in a CM-PRSgw higher donor than the lower donor (Figure 3g), and this 219 
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was partially alleviated by Bardoxolone Methyl (BM), a potent activator of Nuclear factor 220 
like-2 factor17 (Figure 3h). The enhanced antioxidant response induced by BM protects 221 
against hepatocyte death in cholestatic conditions (Figure 3i) even in the CM-PRSgw 222 
higher donor. Collectively, ROS activation may be a potential downstream event prior to 223 
hepatocyte death owing to the accumulation of bile acids and a predisposition to 224 
transcriptional and translational stress substantiated by PRS. 225 
To verify the connection between CM-DILI vulnerable pathways and CM-DILI 226 
drugs, we analysed the risk score associated transcriptomic signatures in PHH from 8 227 
donors under CsA treatment (see Supplementary Table S4) and compared the 228 
transcriptome data in Toxicogenomics Project-Genomics Assisted Toxicity Evaluation 229 
system (TG-GATEs)18 including 941 distinct conditions of drugs-treatment related 230 
changes in transcriptome in PHH (Figure 4a and Supplementary Table S8). First, the 231 
genes highly inactivated in higher CM-PRSgw donors’ PHH were enriched (FDR<0.01) in 232 
pathways such as respiratory electron transport (i.e., inducible mitochondrial toxicity), 233 
translational regulation, and mRNA processing (Figure 4b and Supplementary Table S9), 234 
in concordance with baseline transcriptome analysis in Figure 3. To extend these 235 
findings, we searched for the drugs which inactivated these DILI vulnerable pathways in 236 
TG-GATEs (FDR < 0.01; Supplementary Table S10). Many well-known CM-DILI drugs, 237 
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such as CsA, flutamide, ketoconazole, ranitidine, sulpiride, valproic acid, azathioprine, 238 
decreased levels of genes in these DILI vulnerable pathways (Figure 4c), supporting our 239 
mechanistic findings with CM-DILI inducible drugs in in vitro multi-donor PHH analysis 240 
(Supplementary Table S10). We note that UPR-related genes were also activated in the 241 
higher CM-DILI PRSgw PHH (Figure 4d) as shown in Figure 3. These data suggest that 242 
in silico toxicity modelling, coupled with in vitro genomic and transcriptomic approaches, 243 
may identify compounds with potential for DILI before entering clinical trials. 244 
 This is the first unbiased analysis to implicate genetic variation at the level of 245 
the hepatocyte contributing to DILI susceptibility, validated in an independent clinical 246 
study as well as unrelated donor-derived organoids and primary hepatocytes. 247 
Hepatocyte damage due to an imbalance between formation and clearance of reactive 248 
metabolites, steps that are common for many compounds, is likely upstream events 249 
mediating liver injury19. Once hepatocytes are damaged, innate and adaptive immunity 250 
play a significant role in driving tissue inflammation and injury20, as supported by 251 
identification of HLA alleles and haplotypes as DILI risk factors in GWAS 252 
(Supplementary Note). However, while some of the cases in the iDILIC/DILIN cohort 253 
were shown to have a significant HLA association2, the overall HLA contribution in the 254 
entire cohort is relatively limited. This is similar to TAK-875 DILI, where no HLA 255 
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association has been detected. The PRS (PRSgw+) derived from the expanded 256 
iDILIC/DILIN cohort included mostly flucloxacillin and amoxicillin-clavulanate cases, for 257 
which stronger HLA associations have been demonstrated 21,22 was still useful in 258 
predicting CM-DILI, but not as well as PRSgw. We speculate that this poorer 259 
performance may be due to limited contribution of non-HLA risk factors when HLA is the 260 
main genetic risk factor.  Up to the present, few non-HLA genetic risk factors for any 261 
form of DILI have been identified and replicated, thus highlighting the importance of 262 
aggregating many variants, each making a small contribution to overall DILI risk.  263 
Our PRSgw for CM-DILI revealed shared DILI predictivity across a variety of 264 
drugs independent of their individual chemical characteristics that are considered 265 
important23. This indicates that the make-up of our polygenic scores relates to 266 
intra-hepatocyte mechanisms leading to hepatotoxicity. For example, both UPR and 267 
oxidative stress have been reportedly associated with DILI pathogenesis and cause cell 268 
death due to experimental cholestasis using various drugs such as flucloxacillin, 269 
levofloxacin, diclofenac and carbamazepine24,25. Consistently, our in vitro polygenic 270 
score-based approach, coupled with genomic, transcriptomic, and phenotypic 271 
approaches, indicated that diverse biological pathways including UPR and oxidative 272 
stress responses in hepatocytes contribute to CM-DILI susceptibility (Figure 4e). These 273 
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findings can also provide fundamental mechanisms defining CM-DILI and may 274 
ultimately contribute to the design of safer, efficient, and more robust clinical trials. More 275 
broadly, the proposed “polygenicity-in-a-dish strategy” is a powerful approach to 276 
investigate and interrogate highly complicated pathogenesis in humans with minimal 277 
confounding factors. 278 
 279 
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iDILIC/DILIN GWAS summary statistics 354 
 iDILIC/DILIN GWAS summary statistics (SNP name, minor allele, odds ratio for 355 
the minor allele, and p-value) were kindly provided by researchers in these consortia2. 356 
GWAS were conducted using three types of cohorts, DILI patients (ALL-DILI, n=862), 357 
those with hepatocellular injury (HC-DILI, n=474), and those with cholestatic/mixed 358 
injury (CM-DILI, n=323), against population-matched controls (n=10,588). We used 359 
biallelic and unambiguous SNPs catalogued in snpdb147 and included in the 1000 360 
genome project phase 3 (1KGP3) imputation reference panel (Minimac3 website) 26. 361 
The odds ratios of iDILIC/DILIN GWAS summary statistics were aligned towards the 362 
alternative allele in the reference panel. Finally, 4,392,401 SNPs in ALL-DILI, 4,392,226 363 
SNPs in CM-DILI, and 4,393,472 SNPs in HC-DILI were selected (referred to as 364 
processed iDILIC/DILIN GWAS summary statistics).  365 
 366 
TAK-875 patients and controls collection criteria 367 
Patients comprised individuals treated with TAK-875 monotherapy or combinatorial 368 
therapy. Case (DILI) were identified as subjects receiving TAK-875 and experiencing 369 
within 7 days post treatment a rise in serum Alanine Aminotransferase (ALT) or 370 
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Aspartate Aminotransferase (AST) at least ≥3× upper limits of normal and at least 2x 371 
their baseline value. Otherwise eligible patients who first met the DILI inclusion criteria 372 
more that 7 after final dosing were excluded from the analysis. Control subjects were 373 
randomly identified and did not experience ALT/AST elevations exceeding 10% from 374 
baseline (and not exceeding 3× ULN). Controls were matched in a 3:1 ratio to cases on 375 
the basis of study, drug treatment, race, and sex. 376 
 377 
TAK-875 GWAS 378 
 The study population of the TAK-875 GWAS included subjects experiencing 379 
DILI (cases) and corresponding matched controls as defined above. Data regarding the 380 
patients and controls were collected from TAK-875 Phase 2 and 3 clinical studies. All 381 
studies were conducted in accordance with the Declaration of Helsinki, International 382 
Conference on Harmonization Guidelines for Good Clinical Practice, and all applicable 383 
local regulatory requirements. All studies including protocol and informed consent forms 384 
were approved by the Institutional Review Board (IRB) at each study site. The IRB or 385 
independent ethics committee for each site was constituted according to the applicable 386 
requirements of the participating region, approving the protocol and subject informed 387 
consent. Prior to undergoing any study procedures, signed and dated informed consent 388 
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form was received from each patient. 389 
 We included self-reported Caucasian individuals (Case n=43, Ctrl n=129) for 390 
the GWAS. These subjects were genotyped in a combination of HumanOmni5-Quad 391 
BeadChip (Illumina) and Infinium Human Exome-12 v1.2 BeadChip (Illumina). 392 
Corresponding manifest files of genotyping arrays, HumanOmni5-4v1_B, and 393 
HumanExome-12-v1-2-B, respectively, were used. Quality control (QC) analysis of the 394 
genotyped data checked sample and variant call rate, probe-target duplication, 395 
missingness, heterozygosity, Hardy–Weinberg equilibrium, identity by descent, 396 
ancestors, and minor allele frequency (MAF) using plink software (version v1.90b3.44)27 397 
(see Supplementary Methods). The haplotype phase was estimated using Eagle 398 
software (version 2.3)28 with the 1KGP3 reference panel (provided in Minimac3 website, 399 
version 5, n=2,504). Genotypes of autosomal variants were imputed using Minimac3 400 
software (version 2.0.1) with the 1KGP3 imputation reference panel29. Finally, Case 401 
n=39 and Ctrl n=122 samples with autosomal 13,477,278 variants with a minimac3 402 
imputation quality (Rsq) ≥ 0.7 and non-imputed genotyped 184,010 variants were 403 
included in the GWAS. GWAS was performed using imputed allele dosages of variants 404 
with a MAF > 1% and fitted to an additive genetic model of logistic regression with PC1–405 
PC5 in white GWAS, using snptest software (version 2.5.2)30. A Manhattan plot was 406 
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performed using R package qqman v0.1.2. 407 
 408 
Genetic analysis of shared aetiology 409 
We evaluated shared genetic aetiology between two GWAS summary statistics 410 
using PRSice software (version 1.25)31. Common autosomal SNPs between the 411 
TAK-875 GWAS panel and the processed iDILIC/DILIN GWAS summary statistics were 412 
used. Base summary statistics were pruned from LD-based clumps with parameters 413 
recommended in the PRSice software: clump.p1 0.5, clump.p2 0.5, and clump.kb 300 414 
using plink software (version v1.90b3.44)27. In this clumping step, 1KGP3 European 415 
super population was used and 51,052 SNPs for ALL-DILI, 50,029 SNPs for CM-DILI, 416 
and 50,553 SNPs for HC-DILI were selected. SNPs with OR≠1 in target GWAS sets 417 
were selected. If the β-value for the association of SNPs in TAK-875 GWAS was 418 
positive infinity (negative infinity), secondary maximum (or minimum) β was replaced 419 
with it. Standard errors of datasets were calculated from OR and p-values, using Wald 420 
statistics. Finally, variance explained by the base risk score in target GWAS sets and 421 
p-values were obtained from the PRSice software31. We noted that the increasing trends 422 
are important to show the polygenic architecture in DILI and the levels of variance 423 
explained might be high due to the winner’s curse issue. To avoid incorrect conclusions 424 
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from genetic overlap due to population stratification problem, we only conducted the 425 
summary statistics-based analysis. 426 
 427 
PRS analysis 428 
 From the processed iDILIC/DILIN GWAS summary statistics for the European 429 
LD-based clumped data, we further selected imputable SNP sets from the 1KGP3 430 
reference panel. PRS was calculated as follows: (β for association) × (number of effect 431 
allele for β). The number of alleles was based on the best-guessed genotype upon 432 
1KGP3 imputation with Rsq≥0.7. 433 
 To determine a PRSgw, we considered the cellular context of hepatocytes to 434 
observe the phenotype. Hence, we obtained RNA sequencing (RNA-seq) data of public 435 
primary human hepatocytes (SRR4000958)32. Reads from the FastQ files were mapped 436 
to the GRCh38.p10 reference sequence, using GENCODE v26 annotation file and 437 
STAR software (version 2.5.2b)33, after quality control by FaQCs software (version 438 
1.34)34 with default parameters. FPKM values were obtained using cufflinks software 439 
(version 2.2.1)35, wherein the max-bundle-frags option was adjusted to 109 440 
fragments/locus. Expressed genes (n=14,576) were considered to have an FPKM>0 in 441 
the PHH. Regions 10 kb upstream from the transcription start site to 40 kb downstream 442 
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of the transcription termination site demarcated the coding sequence. Finally, 28,275 443 
SNPs in ALL-DILI, 27,740 SNPs in CM-DILI, and 28,069 SNPs in HC-DILI were 444 
selected (PRSgw). 445 
 Additionally, we developed CM-DILI PRSgw+ from CM-DILI GWAS summary 446 
statistics expanding out data set to 928 European CM-DILI cases due to inclusion of 447 
157 flucloxacillin and 320 amoxicillin-clavulanate DILI patients which had not been 448 
included in the GWAS sets for the CM-DILI PRSgw 
12. For accurate evaluation of 449 
TAK-875 DILI, we used 87,424 SNPs which were clumped by European LD after 450 
filtering for imputation accuracy (Rsq ≥0.7) in TAK-875 GWAS sets to maximize 451 
predictive accuracy for TAK-875 GWAS datasets. Next, in scoring PHH and iPSC, we 452 
used 40,396 SNPs which were clumped by the LD after selecting Hapmap3 SNPs, 453 
because the discovery GWAS used a reference panel (Haplotype Reference 454 
Consortium) that was different from our available LD dataset (1KG European). 455 
 456 
GWAS enrichment analysis 457 
 Enrichment analysis was performed using processed iDILIC/DILIN GWAS 458 
summary statistics. GWAS analysis of regulatory or functional information enrichment 459 
with LD correction (GARFIELD)8 was performed using the default annotation data of the 460 
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software, using R package garfield v1.0.2 under R 3.3.3. Pathway scoring algorithm 461 
(Pascal), integrating GWAS signals from multiple SNPs9, was performed using Pascal 462 
software (downloaded on 6, Jun 2017 from 463 
https://www2.unil.ch/cbg/index.php?title=Pascal). For Pascal analysis, we used the 464 
Molecular Signature Database (MSigDB) v6 gene sets36,37 as pathway information and 465 
default parameters of Pascal: maximum 3,000 SNPs were assigned to a gene and their 466 
average GWAS signal was used for gene scoring, followed by pathway empirical 467 
p-values obtained by their aggregation, considering LD in the European population. 468 
 469 
Cell cultures 470 
PHH were obtained from vendors (Lonza, Basel, Switzerland; KAC, Kyoto, Japan; 471 
Sekisui Medical, Tokyo, Japan) listed in Supplementary Table S4 and cultured in 472 
Hepatocyte Plating Medium (Lonza). Hepatocyte Culture Media (Lonza) was used for 473 
thawing and daily sub-culturing. PHH were plated on Lumox plates (Sarstedt, 474 
Nümbrecht, Germany) coated with 5 µg/cm2 rat tail type-I collagen (Corning, Corning, 475 
NY, USA) in 0.02 mol/L acetic acid. PHH were plated at 4×105 cells per well on a 476 
24-well-type Lumox multiwell plate (Sarstedt) for DNA and RNA extraction and 5×104 477 
cells per well on a 96-well-type Lumox multiwell plate for drug sensitivity assays. After 478 
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24 h of preculture, cells were treated with LCA or 1% DMSO for 1 h. After washing with 479 
PBS, cells were treated with the indicated drugs for viability assay and transcriptome 480 
analysis. 481 
A human iPSC line, 1383D2, was kindly provided by the Center for iPS Cell 482 
Research and Application, Kyoto University. Other human iPSC lines (CW10027, 73-B, 483 
75-A, 10-A, 45-A) were obtained from Coriell institute (NJ, USA) or European Bank for 484 
Induced Pluripotent Stem Cells (EBiSC) (Cambridge, UK). All iPSCs used herein had 485 
normal karyotypes (data not shown). All iPSCs were cultured on laminin 511 486 
E8-fragment-coated (iMatrix-511; Nippi, Tokyo, Japan) dishes in StemFit AK02N 487 
(Ajinomoto, Tokyo, Japan). Directed differentiation methods for each lineage are 488 
described previously13. To generate iPSC-HLOs in vitro, 1.8×106 cells per microwell at a 489 
ratio of 10:7:1 (human iPSC-HE/iPSC-EC/iPSC-STM) were resuspended in a mixture of 490 
endothelial cell growth medium (EGM, Lonza) and HCM containing dexamethasone 491 
(0.1 mM; Sigma-Aldrich, St. Louis, MO, USA), oncostatin M (10 ng/mL; R&D Systems, 492 
Minneapolis, MN, USA), hepatocyte growth factor (HGF) (20 ng/mL, PromoKine, 493 
Heidelberg, Germany), and SingleQuots (Lonza) and plated on 6-well plate of the 494 
Elplasia micro-space cell culture plate (Kuraray, Tokyo, Japan). After 24 h, the 495 
generated iPSC-HLOs were harvested via gentle pipetting and transferred into a 496 
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single-use bioreactor culture system (30 mL; ABLE, Tokyo, Japan) and cultured in the 497 
same media. Further, after differentiation induction for over 10 days, viability testing and 498 
transcriptome after drug addition were performed. Viability testing and transcriptome 499 
were performed on iPSC-HLOs after hepatic differentiation for 10 days and more. 500 
 501 
Drug treatments 502 
 DILI drug compounds were dissolved in DMSO to a final concentration of 1% in 503 
cell culture medium. Each drug was exposed in 3 doses for 24 or 72 hours with or 504 
without LCA 1 hour pre-treatment. The following DILI drugs used in this article 505 
categorized into 2 different DILI; cholestatic/mixed (CM)-DILI drugs: cyclosporin A 506 
(Wako), carbamazepine (Tokyo Chemical Industry), ketoconazole (Sigma), troglitazone 507 
(Wako), bosentan (Toronto Research Chemicals), flutamide (LKT laboratories), 508 
diclofenac (Wako), amoxicillin-clavulanate (amoxicillin; Wako, clavulanate; Matrix 509 
Scientific) and methapyrilene (Toronto Research Chemicals); hepatocellular(HC)-DILI 510 
drugs: tacrine (Cayman), tolcapone (Toris Bioscience) and acetaminophen (Toronto 511 
Research Chemicals). 512 
Transcriptome analysis 513 
 Total RNA was extracted from cultured cells, using a PureLink RNA Mini Kit 514 
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(Thermo Fisher Scientific). A cDNA library was generated from 10 ng of total RNA, using 515 
a SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). Amplification, primer 516 
digestion, and adapter ligation were performed using an Ion AmpliSeq Transcriptome 517 
Human Gene Expression Kit (Thermo Fisher Scientific). The cDNA library was purified 518 
using Agencourt AMPure XP Reagent (Beckman Coulter) and quantified using Ion 519 
Library TaqMan Quantitation Kit (Thermo Fisher Scientific), followed by dilution to 75 pM 520 
with water and pooled equally. Eight samples per pool were sequenced using an Ion 521 
540 Chip Kit (Thermo Fisher Scientific) simultaneously, using IonS5 XL (Life 522 
technologies) and Ion Chef instrument systems (Life technologies) with Ion 540 Kit-Chef 523 
(Life technologies). All procedures were performed per the manufacturers’ protocols. 524 
From the sequencing output, quality control, alignment reads on hg19 525 
(hg19_AmpliSeq_Transcriptome_21K_v1.bed), read counts and the normalization 526 
(reads per million, RPM) for each gene were obtained using the Torrent ampliSeqRNA 527 
plugin (hg19 AmpliSeq Transcriptome ERCC v1) in Torrent Suite Software v5.2.1. 528 
 GSEA for PHH models was performed using GSEA software (v2.2.3, Broad 529 
Institute) in the prerank mode36, using previously described gene sets. The permutation 530 




In-house whole-genome genotyping and PRS calculation 533 
DNA from iPSC and PHH cell was extracted using PureLink Genomic DNA Mini 534 
Kit (Thermo Fisher Scientific) per the manufacturer’s protocols. These subjects were 535 
genotyped using Infinium OmniExpressExome-8 v1.4 BeadChip (Illumina). 536 
Corresponding manifest files of the genotyping array were obtained from Illumina. QC 537 
analysis, haplotype phasing, and genotype imputation the genotyped data were 538 
performed along with the TAK-875 GWAS. Notably, Hardy–Weinberg equilibrium was 539 
not assessed owing to the small sample size; outliers of the known-ancestry cluster 540 
were assessed via PCA for SNPs, using Hapmap3 release338. After genotype 541 
imputation using 1KGP3 reference panel, genotype dosage of variants with a minimac3 542 
imputation quality (Rsq)≥0.7 in a batch was used for calculating PRS similar to 543 
previously described criteria. 544 
 545 
PHH viability assay 546 
PHH viability was determined using a CellTiter-Glo luminescent cell viability 547 
assay kit (Promega) per the manufacturer’s protocol. After pre-treatment with LCA 548 
(Sigma-Aldrich), relative cell viability was determined as a ratio between cell viability of 549 
treated LCA-pre-treated samples and that of control LCA-pre-treated samples. Viability 550 
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upon LCA treatment was calculated as the ratio of cell viability of control 551 
LCA-pre-treated samples and that of control non-pre-treated (1% DMSO treated) 552 
samples. Cell viability was determined for each experimental batch (n=3 in a condition; 553 
n=1-3 batches from available cryopreserved PHH vials). 554 
 555 
iPSC-HLOs viability assay 556 
iPSC-HLO cell viability after drug treatment was determined using a 557 
CellTiter-Glo 3D Cell Viability Assay (Promega) per the manufacturer’s protocol. For 558 
drug evaluation, over 100 iPSC-HLOs were dispensed per one well of low attached 96 559 
well plate. Raw luminescence data were normalized via bright-field images with 560 
Cell3iMager duos (SCREEN Holdings Co., Ltd., Kyoto, Japan) and dividing 561 
luminescence values in the area. 562 
 563 
Live imaging  564 
Indicated molecules or proteins were stained using live cell imaging kits or 565 
antibodies, per the manufacturer’s instructions, as follows: dead cells, LIVE/DEAD Cell 566 
Imaging Kit(488/570) (Thermo); bile acid transport, CLF (BD Biosciences Discovery 567 
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Labware, Franklin Lakes, NJ, USA); reactive oxygen species, CellROX green reagents 568 
(Thermo Fisher Scientific).  569 
 570 
Immunostaining 571 
iPSC-HLOs were fixed in 4% paraformaldehyde (Wako) in PBS for 15 min. 572 
Samples were blocked with Donkey serum (Millipore) and probed with primary 573 
antibodies against Albumin (SIGMA), BSEP (SIGMA), CD31 (BD), CHOP (Santa-Cruz), 574 
and HNF4a (Santa-Cruz) at 4°C overnight. Samples were probed with secondary 575 
antibodies conjugated with Alexa Fluor (Life Technologies) and DAPI (Sigma) for 576 
nuclear staining. Images were acquired using LSM 880 with Airy scan (Zeiss). 577 
 578 
Immunoblot 579 
Drug-treated iPSC-HLOs were suspended in Laemmli sample buffer (BioRad). 580 
Proteins were resolved via SDS-PAGE and electro-transferred onto PVDF membranes 581 
(BioRad). Western blotting was performed per standard protocols, and blotted protein 582 
samples were blocked with Blocking One (Nakarai) for 1 h. Samples were incubated 583 
with anti-KDEL (Enzo), anti-XBP1-s (Cell Signaling), and anti-GAPDH (Cell Signaling) 584 
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primary antibodies at 4°C overnight and probed with horseradish 585 
peroxidase-conjugated secondary IgG (Cell Signaling) for 1 h. Signals enhanced by 586 
ECL Prime (GE Healthcare) were detected using ChemiDoc Touch imaging system 587 
(BioRad). Protein expression levels were measured by Image Lab software (BioRad). 588 
 589 
Enzyme-linked immunosorbent assay (ELISA) 590 
Human albumin (ALB) in was quantified using a Human Albumin ELISA 591 
Quantitation Kit (Bethyl Laboratories Inc., Montgomery, TX, USA) per the 592 
manufacturer’s protocols. 593 
 594 
CYP3A4 activity 595 
Cell-based CYP3A4 activity of iPSC-HLOs was measured using P450-Glo™ 596 
CYP3A4 Assay (Promega) per the manufacturer’s protocols. Raw luminescence data 597 
were normalised using bright-field images with Cell3iMager duos and dividing 598 
luminescence values in the area. 599 
Raw luminescence data were normalized to cell numbers by dividing the P450-Glo 600 




GSH/ GSSG ratio 603 
Changes in GSH/GSSG, oxidative stress indicator, in iPSC-HLOs under drug 604 
treatment was quantified via a luminescence-based GSH/GSSG-Glo assay (Promega) 605 
per the manufacturer’s instructions. 606 
 607 
Transcriptome analysis of multi donor liver tissues 608 
Genotypes and transcriptome data were obtained from ref#16 via 609 
https://www.synapse.org/#!Synapse:syn4492. From curated SNP array dataset 610 
including 349,085 variants and 195 donors, we further performed the following quality 611 
controls: exclude variants with genotype call rate < 95%, Hardy P -value < 10-6, and A/T 612 
or G/C SNPs; exclude individuals in non-European ancestry. From the remaining 613 
213,257 variants and 161 donors, we phased and imputed variants as described above 614 
and calculated their PRS. From DNA microarray-based transcriptome datasets of liver 615 
tissue (40,638 transcripts and 467 donors), we excluded >10% missing donors and ≥1 616 
missing transcripts and aggregated the probe-level datasets into gene-level datasets by 617 
replacing with their average (25,015 transcripts and 157 donors remained). From the 618 
overlapped 156 donors, we calculated coefficient effect of PRSgw on each transcript by 619 
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regressing out the five first transcriptomic PCs to exclude the effects of batch effects in 620 
the transcriptome datasets. Preranked GSEA analysis on Reactome genesets was 621 
performed by using the ranking of their t-statistics. 622 
 623 
Re-analysis of TG-GATEs 624 
Transcriptome data of PHH under drug treatments (2,605 data points including 158 625 
types of drugs, three types of concentration, and three types of exposure times) 626 
measured by GeneChip Human Genome U133 Plus 2.0 array (Affymetrix) was obtained 627 
from the TG-GATEs website (https://toxico.nibiohn.go.jp/english/index.html)18. We 628 
carried out normalization of expression levels using Frozen Robust Multiarray Analysis 629 
using the R package ‘frma’ (version 1.14.0)39 with default parameters and took average 630 
expression levels within replicates. We calculated a signal intensity ratio to each control 631 
data for each probe, took an average value among probe sets for each gene, and made 632 
a gene rank matrix for preranked GSEA analysis. 633 
 634 
Data availability 635 
 The AmpliSeq data used herein are deposited in GEO under accession number 636 
GSE152447. The genotype data for TAK-875 DILI GWAS, the related phenotype 637 
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information, and the summary statistics are stored in Takeda Pharmaceutical Company 638 
Ltd, due to the ethical approval in this study. These datasets are available upon 639 
reasonable request to Takeda Pharmaceutical Company Ltd via the corresponding 640 
author and after being approved by the Ethics Committee of Takeda Pharmaceutical 641 
Company Ltd. Web-links of publicly available datasets are as follows: transcriptome 642 
data of PHH under drug treatments (TG-GATEs), 643 
https://toxico.nibiohn.go.jp/english/index.html; transcriptome data of multi-donor liver 644 
tissues, https://www.synapse.org/#!Synapse:syn4492; transcriptome data of PHH 645 
(SRR4000958), https://trace.ncbi.nlm.nih.gov/Traces/sra/?run=SRR4000958; 646 
GENCODE (v26); https://www.gencodegenes.org; MSigDB (v6),  647 
https://www.gsea-msigdb.org/gsea/msigdb/index.jsp; 1KGP3 imputation reference 648 
panel: https://genome.sph.umich.edu/wiki/Minimac3. 649 
 650 
Code availability 651 
We used publicly available software and parameters as described in this 652 
Methods section for the analysis. The software programs are available from the 653 
following URLs: plink, https://www.cog-genomics.org/plink2/; Minimac3, 654 
https://genome.sph.umich.edu/wiki/Minimac3; snptest, 655 
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https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html; FaQCs, 656 
https://github.com/chienchi/FaQCs; PRSice, http://PRSice.info; STAR, 657 
https://github.com/alexdobin/STAR;  cufflinks, 658 
http://cole-trapnell-lab.github.io/cufflinks/; GARFIELD, 659 
https://www.ebi.ac.uk/birney-srv/GARFIELD/; Pascal; 660 
https://www2.unil.ch/cbg/index.php?title=Pascal; GSEA, 661 
https://www.gsea-msigdb.org/gsea/; R, https://cran.r-project.org/. 662 
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Figure 1. Polygenic architecture of drug induced liver injury (DILI). 729 
(a) Summary of PRS and their sources. (b) Manhattan plot of p-values (logistic 730 
regression model, from snptest software) in TAK-875 white GWAS. Blue line is a 731 
suggestive cut-off (p<1×10-5). (c) Polygenic test using CM-DILI GWAS summary 732 
statistics. X-axis, total number of SNPs, ordered by iDILIC/DILIN GWAS association; 733 
y-axis, explained variance of TAK-875 DILI phenotype from iDILIC/DILIN GWAS 734 
signals; colour scale, one-tail p-value for the shared genetic aetiology test from PRSice 735 
software. The described PGWAS indicated the corresponding thresholds to x-axis. (d) 736 
GARFILD plot of CM-DILI GWAS summary statistics in Nicoletti et al., 2017. Enrichment 737 
in FAIRE-seq (Formaldehyde-Assisted Isolation of Regulatory Elements) annotations in 738 
left and genic state in right. (e) Enriched experimentally known or related pathways 739 
associated with CM-DILI. CM-DILI GWAS summary statistics in Nicoletti et al., 2017 740 
were used. The empirical p-values were from Pascal software. (f) Distribution of PRS in 741 
TAK-875 DILI patients (cases, n=39 individuals) and matched patients treated with 742 
TAK-875 without DILI (controls, n=122 individuals). For each type of PRS, scores were 743 
centred on the median values in controls. *, p < 0.05 (two-tailed Wilcoxon–Mann–744 
Whitney U test; p = 0.0036 for CM-PRSgw, p = 0.70 for HC-PRSgw, p = 0.27 for 745 
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ALL-PRSgw, and p = 0.029 for CM-PRSgw+). For the box plot, the box represented the 746 
first and third quartiles, the center line represented the median, the upper whisker 747 
extended from the hinge to the highest value that is within 1.5 × IQR (inter-quartile 748 
range) of the hinge, the lower whisker extended from the hinge to the lowest value 749 
within 1.5 × IQR of the hinge, and the data beyond the end of the whiskers were plotted 750 
as points. 751 
 752 
Figure 2. Polygenic score based human stratification by in vitro multi-drug 753 
induced CM-DILI assays. 754 
(a) Workflow of comparison. (b) Viability comparison of multi-donor iPSC-HLO models 755 
(triangle) and primary human hepatocytes (circle) under multiple DILI drug treatment. 756 
See Table S4 for donor information per drug 757 
 (c) Comparison of pearson correlation coefficient between the survival rate of the liver 758 
model (mean value for each donor) and the PRS (PRSgw or PRSgw+) under indicated 759 
drugs. *, p < 0.01 (two-tailed Welch's t-test); p = 0.0038 for cholestatic DILI drugs 760 
treatment and p = 0.0005 for hepatocellular DILI drugs treatment.  For the violin plot, 761 
the center point represented the median, the upper whisker extended from the hinge to 762 
the highest value that is within 1.5 IQR (inter-quartile range) of the hinge, the lower 763 
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whisker extended from the hinge to the lowest value within 1.5 IQR of the hinge. 764 
  765 
Figure 3. Mechanistic association studies for CM-DILI vulnerability.  766 
(a) Method to find CM-DILI PRSgw-associated pathways. We performed GSEA analysis 767 
of CM-DILI PRSgw-associated genes, regressing out five first transcriptome principal 768 
components to capture experimental variability15 (b) Pathway enrichment analysis 769 
results for PHH cells and liver tissues. (c) Heatmap analysis of gene sets involved in 770 
unfolded protein response (76 genes) and TCA cycle and respiratory electron transport 771 
(116 genes) (Reactome pathway database40) in multi-donor iPSC-HLO models. (d) 772 
Immunostaining of HNF4a and CHOP under the indicated CsA treatment. The 773 
representative pictures from 2 biological replicates. (e) XBP1s and KDEL levels under 774 
the indicated CsA treatment via immunoblot analysis. GAPDH was used for loading 775 
controls. n=3, independent experiments. (f) Live imaging of oxidative stress induction 776 
using CellROX reagent (ROX), CLF accumulation, and cell death (stained by PI) under 777 
the indicated CsA treatment. The representative pictures from 3 biological replicates. (g) 778 
Comparison of GSH/GSSG ratio in iPSC-HLO model between the PRSgw-high donor 779 
(45A) and the -low donor (CW10027) upon CsA treatment. * ; p=0.017064, a significant 780 
difference between the two groups. n=3, independent experiments. (h) GSH/GSSG 781 
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ratio change by BM treatment in 1383D2 derived iPSC-HLOs under basal condition. 782 
n=2, independent experiments. (i) Cell viability upon BM treatment between PRSgw-high 783 
and -low donor-derived iPSC-HLOs under CsA 50 µM treatment. Significant difference 784 
between the two groups was showed p = 0.0051 with no-treatment, whereas not shown 785 
p = 0.1048 with BM pre-treatment and p=0.0640 with BM pre-/co-treatment. n=3, 786 
independent experiments. All data was shown as mean±SD, *; p < 0.05 (two-tailed 787 
Welch's t-test). 788 
 789 
Figure 4. Polygenic risk score associated transcriptomic signatures associate 790 
with known CM-DILI responses. 791 
 (a) A schematic representation of the protocol for identifying compounds associated 792 
with PRSgw related transcriptomic pathways (see Results and Methods). (b) Heatmap 793 
analysis of gene sets involved in TCA cycle and respiratory electron transport in 8 PHH 794 
donor ordered by PRSgw. This pathway was one of the significantly inactivated 795 
pathways in higher CM-PRSgw donors (Supplementary Table S9). The core enriched 796 
genes in GSEA were shown. (c) Network representation of screened gene sets 797 
associated with CM-DILI PRSgw (FDR < 0.01). Representative clusters and compound 798 
associated with them were indicated. All of the raw results were shown in 799 
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Supplementary Table S9 and S10. (d) Gene expression analysis for representative ER 800 
stress marker genes in the 8 PHH donor under CsA treatment or control condition (see 801 
Methods). **, p < 0.01 (two-sided Pearson correlation test; p = 4.7×10-3) (e) PRSgw 802 
informed CM-DILI vulnerable mechanisms, genetic factors and their relationships. 803 
Green text, validated events by phenotypic assays; Red box, polygenic risk score 804 
informed mechanisms for CM-DILI. 805 














